BCMA-targeted ADC

BCMA-targeted ADC refers to a class of antibody-drug conjugates that bind B-cell maturation antigen (BCMA), a type III transmembrane receptor highly expressed on malignant plasma cells in multiple myeloma and minimally on most normal tissues. These agents comprise an anti-BCMA monoclonal antibody linked via a cleavable or non-cleavable linker to an ultra-potent cytotoxic payload, such as microtubule inhibitors (e.g., monomethyl auristatin F) or DNA/RNA-damaging agents (e.g., pyrrolobenzodiazepine dimers, amanitin), enabling targeted delivery of chemotherapy to BCMA-positive cells while limiting systemic exposure.[1][5][7][8] After binding BCMA, the ADC is internalized and processed in endosomes/lysosomes, releasing the payload to disrupt microtubules or damage DNA/RNA, triggering cell-cycle arrest and apoptosis and thereby providing a targeted immunochemotherapy approach for relapsed or refractory multiple myeloma.[1][5][7][9]